GlaxoSmithKline , a big pharma company, announced a new four year contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the US Department of Health and Human Services , for the provision of its inhalation anthrax treatment, raxibacumab, forming biopharma partners.
The US government is purchasing the medicine as a counter measure against a potential bioterrorist attack.
Under the terms of the new contract, GSK will provide 60,000 doses to the US government over four years, at a value of approximately $196m.
This forms part of a broader five year base contract for the biopharma partners.
Raxibacumab was approved by the FDA in December 2012 for the treatment of adult and pediatric patients with inhalation anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalation anthrax when alternative therapies are not available or are not appropriate.
For further deal information visit Current Agreements (subscription required)
Read: more on GSK company profile, recent partnering, M&A and financing news and articles
Report: Partnering Deals and Alliances with GlaxoSmithKline
Related report: Partnering Deals and Alliances with Big Pharma
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View:Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View:Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity